Breast Nurse Navigator Role Impacts Timeliness of Care for Breast Cancer Patients

August 2012 Vol 3, No 4
Loril Garrett, BSN, RN, OCN, CBPN-IC, CBCN
Spectrum Health, Grand Rapids, Michigan
Geralyn Roobol, RN, BS, LMSW, CMAC
Spectrum Health, Grand Rapids, Michigan
Rebecca Segar, BSN-Student
Spectrum Health, Grand Rapids, Michigan

Background: Breast cancer care is delivered by multiple providers over an extended period of time within an already fragmented healthcare system, which has led to gaps in the care process. The breast nurse navigator (BNN) role seeks to address those gaps and improve patient outcomes. Research is needed to measure the effectiveness of the BNN role in improving patient outcomes.

Objective: To evaluate the impact of the BNN role on the timeliness of care across the breast cancer treatment continuum for the breast cancer population served in our healthcare system.

Methods: The BNN contacted patients within 2 weeks of their breast cancer diagnosis and offered ongoing support and guidance to them. The BNN performed a needs-based assessment with each interaction, which resulted in individualized interventions. Those interventions included providing education, emotional support, advocacy, and help with eliminating barriers to needed care. A retrospective study was conducted comparing breast cancer patients who received BNN services (fiscal year 2010) with those patients who received their care prior to the initiation of our BNN program (fiscal year 2009). Specific intervals were evaluated to assess timeliness of care for each time period; the number of days from breast cancer diagnosis (ductal carcinoma in situ or invasive breast cancer) to first treatment (surgery or chemotherapy), the number of days from surgery to the initiation of adjuvant treatment (chemotherapy, radiation, or antiestrogen therapy), and the number of days between more than 1 adjuvant therapy, as was applicable. Data were collected from the cancer registry, the Michigan Breast Oncology Quality Initiative database, nurse navigation worksheets, and the patients’ electronic medical records.

Results: Timeliness of care from diagnosis to first treatment was improved by 17% overall (reduction of 6.3 days), by 19% for invasive breast cancers (reduction of 6.6 days), and by 29% for those needing neoadjuvant chemotherapy. The overall number of days to first adjuvant treatment was improved by 19% (reduction of 8 days). Statistical analysis confirmed a significant reduction in the number of days from diagnosis to first treatment for patients receiving navigation (t[396] = -3.872, P <.001).

Discussion: The role of navigator includes removing barriers to care, improving patient outcomes, and perfecting the overall quality of healthcare delivery.1 Breast cancer treatment and care can be improved by recognizing the value the nurse navigator role brings to the patient experience and enhancing that role.2 Conclusion: The role of BNN serves as a valuable resource for optimizing patient outcomes by significantly improving the timeliness of treatment and supportive care for breast cancer patients.

References

  1. Pedersen A, Hack TF. Pilots of oncology health care: a concept analysis of the patient navigator role. Oncol Nurs Forum. 2010;37(1):55-60.
  2. Korber SF, Padula C, Gray J, et al. A breast navigator program: barriers, enhancers, and nursing interventions. Oncol Nurs Forum. 2011;38(1):44-50.
Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
|
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country